Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 146

1.

Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.

Jones RL, Demetri GD, Schuetze SM, Milhem M, Elias A, Van Tine BA, Hamm J, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Patel S, von Mehren M.

Ann Oncol. 2018 Sep 1;29(9):1995-2002. doi: 10.1093/annonc/mdy253.

PMID:
30084934
2.

Advances and Challenges on Management of Gastrointestinal Stromal Tumors.

Mei L, Du W, Idowu M, von Mehren M, Boikos SA.

Front Oncol. 2018 May 7;8:135. doi: 10.3389/fonc.2018.00135. eCollection 2018. Review.

3.

Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Keedy V, Kim E, Koon H, Mayerson J, McCarter M, McGarry SV, Meyer C, Morris ZS, O'Donnell RJ, Pappo AS, Paz IB, Petersen IA, Pfeifer JD, Riedel RF, Ruo B, Schuetze S, Tap WD, Wayne JD, Bergman MA, Scavone JL.

J Natl Compr Canc Netw. 2018 May;16(5):536-563. doi: 10.6004/jnccn.2018.0025.

PMID:
29752328
4.

Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.

Schuetze SM, Bolejack V, Thomas DG, von Mehren M, Patel S, Samuels B, Choy E, D'Amato G, Staddon AP, Ganjoo KN, Chow WA, Rushing DA, Forscher CA, Priebat DA, Loeb DM, Chugh R, Okuno S, Reinke DK, Baker LH.

JAMA Oncol. 2018 Jun 1;4(6):814-820. doi: 10.1001/jamaoncol.2018.0601.

PMID:
29710216
5.

Granular cell tumor experience at a comprehensive cancer center.

Moten AS, Movva S, von Mehren M, Wu H, Esnaola NF, Reddy SS, Farma JM.

J Surg Res. 2018 Jun;226:1-7. doi: 10.1016/j.jss.2018.01.027. Epub 2018 Feb 9.

PMID:
29661274
6.

Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene.

Indio V, Astolfi A, Tarantino G, Urbini M, Patterson J, Nannini M, Saponara M, Gatto L, Santini D, do Valle IF, Castellani G, Remondini D, Fiorentino M, von Mehren M, Brandi G, Biasco G, Heinrich MC, Pantaleo MA.

Int J Mol Sci. 2018 Mar 4;19(3). pii: E732. doi: 10.3390/ijms19030732.

7.

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Coccia PF, Pappo AS, Beaupin L, Borges VF, Borinstein SC, Chugh R, Dinner S, Folbrecht J, Frazier AL, Goldsby R, Gubin A, Hayashi R, Huang MS, Link MP, Livingston JA, Matloub Y, Millard F, Oeffinger KC, Puccetti D, Reed D, Robinson S, Rosenberg AR, Sanft T, Spraker-Perlman HL, von Mehren M, Wechsler DS, Whelan KF, Yeager N, Gurski LA, Shead DA.

J Natl Compr Canc Netw. 2018 Jan;16(1):66-97. doi: 10.6004/jnccn.2018.0001.

PMID:
29295883
8.

Gastrointestinal Stromal Tumors.

von Mehren M, Joensuu H.

J Clin Oncol. 2018 Jan 10;36(2):136-143. doi: 10.1200/JCO.2017.74.9705. Epub 2017 Dec 8.

PMID:
29220298
9.

Emerging drugs for the treatment of gastrointestinal stromal tumour.

Kasireddy V, von Mehren M.

Expert Opin Emerg Drugs. 2017 Dec;22(4):317-329. doi: 10.1080/14728214.2017.1411479. Epub 2017 Dec 18. Review.

PMID:
29183145
10.

Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.

Calvo E, Azaro A, Rodon J, Dirix L, Huizing M, Senecal FM, LoRusso P, Yee L, Poggesi I, de Jong J, Triantos S, Park YC, Knoblauch RE, Parekh TV, Demetri GD, von Mehren M.

Invest New Drugs. 2018 Jun;36(3):476-486. doi: 10.1007/s10637-017-0546-9. Epub 2017 Nov 27.

PMID:
29177975
11.

Distress and Financial Distress in Adults With Cancer: An Age-Based Analysis.

Meeker CR, Wong YN, Egleston BL, Hall MJ, Plimack ER, Martin LP, von Mehren M, Lewis BR, Geynisman DM.

J Natl Compr Canc Netw. 2017 Oct;15(10):1224-1233. doi: 10.6004/jnccn.2017.0161.

PMID:
28982748
12.

Randomized Clinical Trials in Gastrointestinal Stromal Tumors.

Liu Y, von Mehren M.

Surg Oncol Clin N Am. 2017 Oct;26(4):545-557. doi: 10.1016/j.soc.2017.05.004. Epub 2017 Aug 4. Review.

PMID:
28923219
13.

Succinate dehydrogenase deficiency in a PDGFRA mutated GIST.

Belinsky MG, Cai KQ, Zhou Y, Luo B, Pei J, Rink L, von Mehren M.

BMC Cancer. 2017 Aug 2;17(1):512. doi: 10.1186/s12885-017-3499-7. Review.

14.

Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.

Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD.

Gynecol Oncol. 2017 Sep;146(3):531-537. doi: 10.1016/j.ygyno.2017.06.018. Epub 2017 Jun 24.

15.

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.

Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebat DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH.

JAMA Oncol. 2017 Jul 1;3(7):944-952. doi: 10.1001/jamaoncol.2016.6728.

16.

Duodenal-Jejunal Flexure GI Stromal Tumor Frequently Heralds Somatic NF1 and Notch Pathway Mutations.

Burgoyne AM, De Siena M, Alkhuziem M, Tang CM, Medina B, Fanta PT, Belinsky MG, von Mehren M, Thorson JA, Madlensky L, Bowler T, D'Angelo F, Stupack DG, Harismendy O, DeMatteo RP, Sicklick JK.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00014. Epub 2017 Aug 15.

17.

Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic.

Weldon CB, Madenci AL, Boikos SA, Janeway KA, George S, von Mehren M, Pappo AS, Schiffman JD, Wright J, Trent JC, Pacak K, Stratakis CA, Helman LJ, La Quaglia MP.

J Clin Oncol. 2017 Feb 10;35(5):523-528. doi: 10.1200/JCO.2016.68.6733. Epub 2016 Dec 28.

18.

Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor.

Schuetze SM, Bolejack V, Choy E, Ganjoo KN, Staddon AP, Chow WA, Tawbi HA, Samuels BL, Patel SR, von Mehren M, D'Amato G, Leu KM, Loeb DM, Forscher CA, Milhem MM, Rushing DA, Lucas DR, Chugh R, Reinke DK, Baker LH.

Cancer. 2017 Jan 1;123(1):90-97. doi: 10.1002/cncr.30379. Epub 2016 Oct 3.

19.

Efficacy of trabectedin for the treatment of liposarcoma.

Zijoo R, von Mehren M.

Expert Opin Pharmacother. 2016 Oct;17(14):1953-62. doi: 10.1080/14656566.2016.1229304. Epub 2016 Sep 15. Review.

PMID:
27615729
20.

Management of Gastrointestinal Stromal Tumors.

von Mehren M.

Surg Clin North Am. 2016 Oct;96(5):1059-75. doi: 10.1016/j.suc.2016.05.011. Review.

PMID:
27542643

Supplemental Content

Loading ...
Support Center